Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphodiesterase type 1 (PDE1) is an enzyme family that regulates the intracellular levels of the second messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). PDE1 is unique among phosphodiesterases as it is activated by calcium/calmodulin (Ca2+/CaM), making its activity dependent on intracellular calcium levels. The PDE1 family includes three main genes/isoforms: PDE1A, PDE1B, and PDE1C. Isoform differences affect substrate specificity. By regulating cAMP/cGMP signaling pathways, PDE1 enzymes play roles in memory formation, cardiac function, smooth muscle activity and more. Dysregulation is implicated in neurodegenerative diseases, cardiovascular disorders, metabolic syndromes, certain cancers, renal pathologies, and pulmonary hypertension. Selective inhibition or modulation of specific PDE1 isoforms is being explored for therapeutic intervention but challenges remain regarding selectivity due to high homology between isoforms/subtypes within the family.
Phosphodiesterase 1 Inhibitors
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphodiesterase type 1 (PDE1).